Biomind Labs (Biomind Labs) Debt-to-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Debt-to-Asset?

Biomind Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Biomind Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Biomind Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $0.16 Mil. Biomind Labs's debt to asset for the quarter that ended in Sep. 2023 was 0.00.

Biomind Labs Debt-to-Asset Historical Data

The historical data trend for Biomind Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Debt-to-Asset Chart

Biomind Labs Annual Data

Trend

Dec21

Dec22

Debt-to-Asset

0.02

0.09

Biomind Labs Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial						0.04	0.09	-	-	-

Competitive Comparison of Biomind Labs's Debt-to-Asset

For the Biotechnology subindustry, Biomind Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomind Labs's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Debt-to-Asset falls into.

Biomind Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biomind Labs's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.008	+	0)	/	0.089
	=	0.09

Biomind Labs's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0.158
	=	0.00

Biomind Labs (OTCPK:BMNDF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biomind Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomind Labs (Biomind Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (OTCPK:BMNDF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

3XI:Germany BMND:Canada

Address

Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000

Website

https://www.biomindlabs.com

Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (Biomind Labs) Headlines

No Headlines